**Core tip:** This retrospective cohort study describes the feasibility, safety, and effectiveness of inserting a biliary spontaneous dislodgement spiral stent (BSDSS) for patients who underwent mechanical lithotripsy for large stone removal. All BSDSSs were inserted successfully and evacuated spontaneously after a median duration of 3 d without additional injuries to the digestive tract. Comparable results of post-endoscopic retrograde cholangiopancreatography adverse events, drainage time, and length of postoperative stay were observed in the BSDSS group (*n* = 21) and the nasobiliary tube group (*n* = 28).

INTRODUCTION
============

Endoscopic retrograde cholangiopancreatography (ERCP) is one of the main methods of removing biliary stones in the common bile duct (CBD)\[[@B1]-[@B3]\]. Endoscopic sphincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) are the most commonly used modalities for stone removal\[[@B1]-[@B3]\], but mechanical lithotripsy (ML) may also be required to remove large biliary stones. ML is the simplest method to fragment large CBD stones, but it carries the risk of remaining debris (including small fragments and sludge), even in patients with successful stone removal according to the judgment of the operating endoscopists. In general, placement of a nasobiliary tube or a conventional plastic biliary stent\[[@B4]\] can be performed in this setting, but the applications of both devices have obvious shortcomings. Patients with nasobiliary tubes may suffer from significant discomfort due to the transnasal placement\[[@B5],[@B6]\], which could lead to self-extraction and dislocation of the tube; additionally, bile loss caused by external drainage can lead to electrolyte imbalance\[[@B5],[@B6]\], which is especially risky for patients with arrhythmia. Patients with conventional plastic biliary stents have to undergo another endoscopy for stent removal\[[@B6]\], which incurs additional medical costs. We developed a biliary spontaneous dislodgement spiral stent (BSDSS) to overcome the above shortcomings of nasobiliary tubes and conventional biliary stents\[[@B7],[@B8]\]. This retrospective cohort study assessed the feasibility, safety, and effectiveness of the placement of a BSDSS for patients who underwent ML for large stone (≥ 10 mm) removal by comparing the clinical outcomes of BSDSS patients with those of nasobiliary tube patients.

 

 

 

MATERIALS AND METHODS
=====================

Study design
------------

This single-center, retrospective cohort study was conducted at West China Hospital, Sichuan University, a tertiary hospital. The study protocol was approved by the Biomedical Research Ethics Committee, West China Hospital, Sichuan University.

Design of the BSDSS
-------------------

The BSDSS used in this study is made of soft and pliable thermoplastic polyurethane, which is different from the commonly used plastic biliary stent (polyte-trafluoroethylene). The main difference in shape between the BSDSS and the conventional plastic biliary stent is the duodenal end (Figure [1](#F1){ref-type="fig"}). The BSDSS has more than one spiral, whereas the conventional has no or only one spiral (straight type and pigtail type, respectively). There are several side holes in the spirals of the BSDSS, and the diameter of the spirals is 12 mm. Another difference lies in the shape of the flanges in the bile duct end. Unlike the long flanges in the conventional stents, the BSDSSs have two short, thin flanges. The outer diameter of the BSDSS is 7 Fr, and its length is 7 cm.

![Biliary spontaneous dislodgement spiral stent and its clinical application in a patient who underwent mechanical lithotripsy for large stone removal. A: the 7-cm × 7-Fr biliary spontaneous dislodgement spiral stent with 12-mm spirals; B and C: the endoscopic and fluoroscopic view of the biliary spontaneous dislodgement spiral stent, respectively, after insertion into the common bile duct.](WJG-26-740-g001){#F1}

Patients
--------

Consecutive patients with large biliary stones (≥ 10 mm) who underwent ML for stone removal between November 2017 and July 2018 were retrospectively collected from our prospectively collected database and the hospital medical records. The exclusion criteria were as follows: (1) Patients with altered anatomy; (2) Patients with percutaneous transhepatic cholangial drainage; (3) Patients with biliary stricture; (4) Patients with intrahepatic stones; and (5) Patients with incomplete stone removal (including failed ML and intolerance to repeated stone extraction).

ERCP procedures
---------------

All ERCP procedures were performed by an experienced endoscopist who underwent \> 300 ERCP procedures per year. Patients were administered diazepam, pethidine, and anisodamine for conscious sedation, pain control, and bowel relaxation. ERCP was performed in the prone position using a standard duodenoscope (TJF-260V; Olympus, Tokyo, Japan). After selective cannulation of the CBD, a minimum of 25% omnipaque was injected to confirm the number and size of CBD stones. According to the endoscopist's judgment, limited EST (3-5 mm), with or without small EPBD (8-10 mm), was performed to facilitate stone removal, followed by the application of ML. A trapezoid RX wire-guided retrieval basket (Boston Scientific Corporation; Marlborough, MA, USA) was used to fragment the stone, and then a grasping basket (FG-22Q-1; Olympus, Tokyo, Japan) was applied to extract fragments repeatedly.

For patients with nasobiliary tubes, a nasobiliary tube (7 Fr; Micro-Tech (Nanjing) Co., Ltd, Nanjing, China) was inserted into the intrahepatic duct using routine instruments and methods\[[@B5]\]. For patients with BSDSSs, a BSDSS \[7 Fr × 7 cm; Micro-Tech (Nanjing) Co., Ltd, Nanjing, China\] was advanced into the CBD using a guide wire (Jagwire^TM^; Boston Scientific, Natick, MA, USA) aided by a plastic stent introduction device. The BSDSS was then released under fluoroscopic guidance, leaving the duodenal end with spirals outside the duodenal papilla. The BSDSS location was adjusted by the stent introduction device or endoscopic forceps according to the reference mark. Drainage of bile, small fragments or sludge, were confirmed before withdrawal of the duodenoscope.

Post-ERCP management
--------------------

After the procedure, the patients fasted for at least 24 h. Blood tests, including complete blood counts, liver function tests, and pancreatic enzymes, were performed 6-48 h after the procedure. Computed tomography (CT) or magnetic resonance cholangiopancreatography (MRCP) was performed when needed. Daily abdominal radiography was scheduled to determine the BSDSS location until the BSDSS was noted when the patient had a bowel movement. Postoperative cholangiography (for patients with nasobiliary tube and without self-extraction or dislocation of nasobiliary tube) or abdominal ultrasound (for patient with BSDSS, and for patients with nasobiliary tube but with self-extraction or dislocation of nasobiliary tube) was performed to detect residual debris, and additional ERCP was performed when needed. Cholecystectomy was recommended for patients with cystic stones.

Patients were followed *via* clinical visits every 3-6 mo, during which clinical symptoms and laboratory tests including liver function tests were recorded; abdominal ultrasound, CT, or MRCP were performed to identify CBD stone recurrence. Follow-up for each patient was discontinued till CBD stone recurrence or October 2019.

Outcome measurements
--------------------

We evaluated the technical success, post-ERCP adverse events, drainage time, and postoperative stay.

Technical success was defined as the successful insertion of the BSDSS or nasobiliary tube into the bile duct in an appropriate position based on endoscopic and fluoroscopic confirmation.

Post-ERCP adverse events mainly included post-ERCP cholangitis (PEC), post-ERCP pancreatitis (PEP) and CBD stone recurrence. Other events relevant to the BSDSS (BSDSS retention and BSDSS-related injuries to the digestive tract) or nasobiliary tube (self-extraction and dislocation of the nasobiliary tube) were also recorded. PEC was defined as a fever (\> 38°C), leukocytosis, and evidence of cholestasis\[[@B9]\]. PEP was defined as persistent pain associated with a serum amylase (or serum lipase) level ≥ 3 times the normal upper limit.\[[@B9]\] As a recent study\[[@B10]\] revealed that the revised Atlanta criteria\[[@B11]\] better reflect the severity of PEP than a previous consensus by Cotton et al\[[@B12]\], the revised Atlanta classification was used as a grading standard in this study. CBD stone recurrence was defined as the observation of CBD stones six months or more after ERCP\[[@B13]\].

Because BSDSS dislodgement cannot be precisely detected, the duration from BSDSS placement to evacuation (*i.e*., evacuation time) was measured as the drainage time for the BSDSS. For patients with nasobiliary tubes, the drainage time was defined as the duration from tube placement to tube extraction.

Postoperative stay was defined as the duration from the ERCP procedure to discharge. For patients who underwent additional ERCP to remove residual debris during the same hospitalization, the postoperative stay was calculated from the initial ERCP to discharge.

Statistical analysis
--------------------

SPSS 25.0 was used for statistical analysis. Numerical variables are expressed as the means (standard deviations) or medians (interquartile ranges, IQRs) according to their distribution and were compared using Student's *t* test or Mann-Whitney *U*-test, accordingly. Categorical variables are expressed as the numbers or proportions and were compared using *χ*^2^ tests or Fisher's exact tests as appropriate. *P* values \< 0.05 were considered significant.

RESULTS
=======

From November 2017 to July 2018, a total of 91 patients with large biliary stones (≥ 10 mm) underwent ML for stone removal (Figure [2](#F2){ref-type="fig"}), and 49 patients met the criteria for inclusion in this study. Among these 49 patients, 21 underwent endoscopic placement of a BSDSS, while the other 28 patients underwent endoscopic placement of a nasobiliary tube. The baseline characteristics and clinical information in each group were similar (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics and clinical information of the biliary spontaneous dislodgement spiral stent and nasobiliary groups, *n* (%)

                                                       **BSDSS group (*n* = 21)**   **Nasobiliary tube group (*n* = 28)**   ***P* value**
  ---------------------------------------------------- ---------------------------- --------------------------------------- ---------------------------------------
  Age, mean ± SD, yr                                   64 ± 16                      67 ± 19                                 0.572[5](#T1FN5){ref-type="table-fn"}
  Sex, male/female                                     11/10                        13/15                                   0.680[6](#T1FN6){ref-type="table-fn"}
  Diagnosis                                                                                                                 0.951[7](#T1FN7){ref-type="table-fn"}
  Biliary colic                                        6 (28.6)                     10 (35.7)                               
  Obstructive jaundice                                 7 (33.3)                     8 (28.6)                                
  Acute cholangitis[1](#T1FN1){ref-type="table-fn"}    6 (28.6)                     7 (25.0)                                
  Acute pancreatitis[1](#T1FN1){ref-type="table-fn"}   2 (9.5)                      3 (10.7)                                
  Comorbidity[2](#T1FN2){ref-type="table-fn"}          10 (47.6)                    18 (64.3)                               0.243[6](#T1FN6){ref-type="table-fn"}
  Gallbladder status                                                                                                        0.410[7](#T1FN7){ref-type="table-fn"}
  Post cholecystectomy                                 12 (57.1)                    13 (46.4)                               
  Cholecystectomy after ERCP                           2 (9.5)                      1 (3.6)                                 
  Gallbladder stones *in situ*                         5 (23.8)                     6 (21.4)                                
  No gallbladder stones                                2 (9.5)                      8 (28.6)                                
  Previous EST                                         2 (9.5)                      6 (21.4)                                0.438[7](#T1FN7){ref-type="table-fn"}
  Periampullary diverticulum                           11 (52.4)                    12 (42.9)                               0.509[6](#T1FN6){ref-type="table-fn"}
  Maximum CBD diameter, median (IQR), mm               13 (12-16)                   15 (13-15)                              0.214[8](#T1FN8){ref-type="table-fn"}
  Maximum stone diameter, median (IQR), mm             13 (11-16)                   12 (12-15)                              0.581[8](#T1FN8){ref-type="table-fn"}
  Minimum stone diameter, median (IQR), mm             10 (9-12)                    12 (10-12)                              0.761[8](#T1FN8){ref-type="table-fn"}
  Stones number, \< 3/≥ 3                              14/7                         25/3                                    0.076[6](#T1FN6){ref-type="table-fn"}
  ERCP modalities for stone removal                                                                                         0.595[7](#T1FN7){ref-type="table-fn"}
  ML[3](#T1FN3){ref-type="table-fn"}                   1 (4.8)                      4 (14.3)                                
  EST + ML                                             3 (14.3)                     6 (21.4)                                
  EPBD + ML[3](#T1FN3){ref-type="table-fn"}            1 (4.8)                      2 (7.1)                                 
  EST + EPBD + ML                                      16 (76.2)                    16 (57.1)                               
  Residual debris[4](#T1FN4){ref-type="table-fn"}      1 (4.8)                      5 (17.9)                                0.219[7](#T1FN7){ref-type="table-fn"}

Endoscopic retrograde cholangiopancreatography was performed when acute cholangitis and acute pancreatitis were controlled;

Hypertension, coronary artery disease, diabetes mellitus, chronic obstructive pulmonary disease, liver cirrhosis, neoplastic diseases in other systems;

These patients underwent endoscopic sphincterotomy for stone removal previously;

Residual debris was detected by abdominal ultrasound in the only one patient in the biliary spontaneous dislodgement spiral stent group; Residual debris was detected by postoperative cholangiography in four patients in the nasobiliary tube group, while the remaining one patient was confirmed by abdominal ultrasound owing to dislocation of the nasobiliary tube. All these 6 patients underwent additional endoscopic retrograde cholangiopancreatography for debris removal;

Student's *t* test;

*χ*^2^ test;

Fisher exact test;

Mann-Whitney *U*-test. BSDSS: Biliary spontaneous dislodgement spiral stent; ERCP: Endoscopic retrograde cholangiopancreatography; CBD: Common bile duct; IQR: Interquartile range; EST: Endoscopic sphincterotomy; ML: Mechanical lithotripsy; EPBD: Endoscopic papillary balloon dilation.

![Study flowchart of patient selection. CBD: Common bile duct; PTCD: Percutaneous transhepatic cholangial drainage; BSDSS: Biliary spontaneous dislodgement spiral stent; ERCP: Endoscopic retrograde cholangiopancreatography.](WJG-26-740-g002){#F2}

The clinical outcomes in the two groups are shown in Table [2](#T2){ref-type="table"}. Insertion of the BSDSS or nasobiliary tube was technically successful with a single attempt in all 49 patients. There was no need to use forceps to adjust the location of the BSDSS. There was no PEC in the two groups, but mild PEP was noted in one patient in the BSDSS group (4.8%, 1/21) and one in the nasobiliary tube group (3.6%, 1/28); which was controlled in both patients with conservative treatment. During a median follow-up of 18 mo (IQR, 15-21; range, 13-23), CBD stone recurrence was detected in one patient in the nasobiliary tube group (3.6%, 1/28), and additional ERCP was performed to remove the recurrent stone. In addition, all BSDSSs were dislodged and evacuated spontaneously after a median duration of 3 d (IQR, 3-5; range, 2-8), without additional injuries to the digestive tract; most patients (76.2%, 16/21) noticed the dislodged BSDSS when they had a bowel movement. Two patients in the nasobiliary tube (7.1%, 2/28) extracted the tube by themselves on postoperative day 1, due to intolerance of the transnasal placement of the tube; dislocation of the nasobiliary tube was also noted in 1 patient in the nasobiliary tube group (3.6%, 1/28). There were no significant differences in the incidence of overall post-ERCP adverse events (4.8% in the BSDSS group *vs* 17.9% in the nasobiliary tube group, *P* = 0.219).

###### 

Clinical outcomes of the biliary spontaneous dislodgement spiral stent and nasobiliary tube groups, *n* (%)

                                                                   **BSDSS group (*n* = 21)**   **Nasobiliary tube group (*n* = 28)**   ***P* value**
  ---------------------------------------------------------------- ---------------------------- --------------------------------------- ---------------------------------------
  Technical success                                                21 (100)                     28 (100)                                \-
  Overall post-ERCP adverse events                                 1 (4.8)                      5 (17.9)                                0.219[4](#T2FN4){ref-type="table-fn"}
  Cholangitis                                                      0 (0)                        0 (0)                                   \-
  Pancreatitis[1](#T2FN1){ref-type="table-fn"}                     1 (4.8)                      1 (3.6)                                 1.000[4](#T2FN4){ref-type="table-fn"}
  CBD stone recurrence                                             0 (0)                        1 (3.6)                                 1.000[4](#T2FN4){ref-type="table-fn"}
  Other events[2](#T2FN2){ref-type="table-fn"}                     0 (0)                        3 (10.7)                                0.250[4](#T2FN4){ref-type="table-fn"}
  Follow-up duration, median (IQR), mo                             19 (17-22)                   18 (15-21)                              0.365[5](#T2FN5){ref-type="table-fn"}
  Drainage time[3](#T2FN3){ref-type="table-fn"}, median (IQR), d   3 (3-5)                      4 (2-5)                                 0.934[5](#T2FN5){ref-type="table-fn"}
  Postoperative stay, median (IQR), d                              4 (3-6)                      5 (3-7)                                 0.223[5](#T2FN5){ref-type="table-fn"}

Pancreatitis was graded as mild in both groups;

There was no biliary spontaneous dislodgement spiral stent (BSDSS) retention in the BSDSS group, while self-extraction (*n* = 2) and dislocation (*n* = 1) of the nasobiliary tube was noted in three patients in the nasobiliary tube group;

Drainage time was defined as the duration from insertion to evacuation in the BSDSS group and the duration from insertion to extraction in the nasobiliary tube group;

Fisher exact test;

Mann-Whitney *U*-test. BSDSS: Biliary spontaneous dislodgement spiral stent; ERCP: Endoscopic retrograde cholangiopancreatography; CBD: Common bile duct; IQR: Interquartile range.

The median drainage time in the BSDSS group was 3 d and that in the nasobiliary tube group was 4 d, without a significant difference between the groups (*P* = 0.934). The median length of postoperative stay was also similar in the two groups (4 d in the BSDSS group *vs* 5 d in the nasobiliary tube group, *P* = 0.223).

DISCUSSION
==========

This retrospective cohort study was conducted to evaluate the feasibility of the placement of a BSDSS for patients who underwent ML for large stone (≥ 10 mm) removal. All inserted BSDSSs were dislodged and evacuated spontaneously without additional injuries to the digestive tract, and the incidence of post-ERCP adverse events in the BSDSS group was low and comparable with that in the nasobiliary tube group. Although the duration from BSDSS placement to evacuation was uncontrollable, similar results in terms of the drainage time and postoperative stay were noted in the two groups. Our findings show the feasibility, safety, and effectiveness of BSDSS for patients who underwent ML for large stone removal.

Apart from EST and EPBD, ML is helpful for removing large stones due to its ability to fragment stones, but the rate of PEC after ML can be high (13.3%, 6/45)\[[@B4]\]. Residual small fragments or sludge, as well as injuries to the biliary tract and papillary edema caused by repeated manipulations, may be potential causes. The use of a nasobiliary tube in patients who underwent ML ensures the direct evaluation of the drainage characteristics and facilitates postoperative cholangiography to detect residual debris. However, external drainage from the nasobiliary tube could cause significant discomfort due to the transnasal placement and bile loss. Discomfort in the nostril and throat may lead to self-extraction and dislocation of the nasobiliary tube\[[@B14]\], which was noted in 3 patients with nasobiliary tubes in this study (10.7%, 3/28). Tube kinking, compression ulcers, and aspiration pneumonia can also occur\[[@B5],[@B6],[@B15]\]. Although external drainage-induced electrolyte imbalance, such as hypokalemia, is uncommon during short-term biliary drainage (0% in this study), it is risky for patients with arrhythmia once developed. In addition, abdominal ultrasound can be applied to detect residual debris as a substitute for postoperative cholangiography. As shown in Table [1](#T1){ref-type="table"}, residual debris was detected by abdominal ultrasound in one patient in the BSDSS group and one patient in the nasobiliary tube group who underwent additional ERCP for debris removal. Given the above, the application of a BSDSS avoids the nasobiliary tube-related medical risks and improves the quality of life of patients.

Compared with conventional plastic biliary stents, the main strength of the BSDSS is its ability to dislodge and evacuate spontaneously after a short period of internal biliary drainage, which was noted in all patients in this study (100%, 21/21). We postulate that the BSDSS is dislodged after papillary edema abates, with the help of bowel movements and/or the passage of high-fiber chyme. In contrast, only 5%-10% of conventional plastic biliary stents can migrate distally\[[@B16]\]; thus, additional endoscopy is frequently required for stent removal. In addition, the BSDSS is soft and has several spirals on the duodenal side, which makes it less likely to lead to stent-related bowel perforation or fistula that have been reported previously in patients with conventional plastic biliary stents\[[@B17]-[@B21]\].

The main disadvantage of BSDSS is the lack of control over the timing of dislodgement and evacuation. The length of EST, as well as the size of EPBD, may seriously affect BSDSS dislodgement. For patients who underwent complete EST (and/or large EPBD), the BSDSS may be dislodged within a couple of hours because of the large opening of the papilla; thus, the application of a BSDSS in these patients seems unadvisable. However, as reported by previous studies\[[@B22]-[@B24]\], complete EST and large EPBD (12-20 mm) have been regarded to be associated with a higher rate of late adverse events; thus, our routines of performing limited (3-5 mm) EST, small (8-10 mm) EPBD and ML for large stone removal seem reasonable. In addition, we used daily radiography to identify the BSDSS location in this study, but BSDSS dislodgement still could not be detected accurately, and there may be a significant difference in the duration from BSDSS dislodgment to evacuation among patients. Because all BSDSSs were evacuated spontaneously after a median duration of 3 d (IQR, 3-5), daily radiography may not be necessary due to increased radiation exposure. We suggest that single radiography on postoperative day 5 may be preferable for patients with BSDSS if they ignore the evacuated BSDSS when they have a bowel movement. Further methods may be proposed for determining the real-time positioning of BSDSS and to clarify the real drainage time with the BSDSS.

The biodegradable stent reported by Anderloni et al\[[@B25]\] ensures different degradation times for distinct clinical demands using various polymeric mixtures, making it a promising stent for patients who underwent ML; however, the use of such biodegradable stents should be approached cautiously because partially degraded stents may impair normal drainage and affect the findings of follow-up abdominal imaging.

The present study had several limitations. First, it was a single-center, retrospective study with a small sample size, but consecutive patients who underwent ML for large stone removal were included, which helps reduce the selection bias. Prospective, multicenter, and large-scale studies are needed to further evaluate the role of BSDSSs in such patients. Second, a comparison with the conventional plastic biliary stent was absent. This is mainly due to the rare use of conventional plastic stents in patients who underwent successful stone extraction after ML in our endoscopy center; these patients routinely received nasobiliary tube before the introduction of BSDSS. Third, there was no comparative group without drainage, and thus, the necessity of placing a BSDSS needs to be further investigated. Although the three patients with tube self-extraction or dislocation in the nasobiliary tube group did not develop PEC, considering the reported high incidence of PEC in patients who underwent ML for stone removal (13.3%, 6/45)\[[@B4]\], a comparative study regarding the placement of BSDSS *vs* no BSDSS should be carefully conducted.

In conclusion, endoscopic placement of a BSDSS in patients who underwent ML for large stone removal appears to be feasible, safe and effective.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) cholangitis (PEC) in patients who underwent mechanical lithotripsy (ML) for large stone removal is high (up to 13.3%). One of the main causes is remaining small fragments or sludge that can impair normal biliary drainage. Endoscopic placement of a nasobiliary tube or a conventional plastic biliary stent was commonly used under such conditions, but the patient may suffer from significant discomfort after the placement of a nasobiliary tube, while additional endoscopy is required for stent removal.

Research motivation
-------------------

We developed a biliary spontaneous dislodgement spiral stent (BSDSS) to overcome nasobiliary tube-related and conventional plastic biliary stent-related shortcomings. The duodenal end of the BSDSS is with several spirals, and its bile duct end has two short and thin flanges. We postulate that the BSDSS is dislodged after papillary edema abates, with the help of bowel movements and/or the passage of high-fiber chyme.

Research objectives
-------------------

In this retrospective cohort study, we evaluated the feasibility, safety, and effectiveness of inserting a BSDSS for patients who underwent ML for large stone removal by comparing the clinical outcomes of BSDSS patients with those of nasobiliary tube patients.

Research methods
----------------

From November 2017 to July 2018, a total of 91 consecutive patients underwent ML for large (≥ 10 mm) stone removal. Of these, 49 patients were eligible for this study, and they were divided into the BSDSS group and the nasobiliary tube group. Technical success, post-ERCP adverse events (including PEC, post-ERCP pancreatitis, stone recurrence, BSDSS retention, self-extraction and dislocation of the nasobiliary tube), drainage time, and postoperative stay were measured and compared.

Research results
----------------

Twenty-one patients in the BSDSS group and 28 patients in the nasobiliary tube group were included in the analyses. The baseline characteristics and clinical information were similar in the two groups. Insertions of BSDSS and nasobiliary tube were technically successful in all 49 patients. There was no significant difference in the incidence of overall post-ERCP adverse events between the two groups (4.8% in the BSDSS group *vs* 17.9% in the nasobiliary tube group, *P* = 0.219), as well as the median duration of drainage time (3 d in the BSDSS group *vs* 4 d in the nasobiliary tube group, *P* = 0.934) and the median length of postoperative stay (4 d in the BSDSS group *vs* 5 d in the nasobiliary tube group, *P* = 0.223).

Research conclusions
--------------------

Endoscopic placement of a BSDSS appears to be feasible, safe and effective for patients who underwent ML for large stone removal.

Research perspectives
---------------------

Multi-center studies with a large sample size are warranted to further confirm the safety and effectiveness of BSDSS. Comparative study regarding the placement of BSDSS *vs* no BSDSS is expected to clarify the necessity of routine application of BSDSS in patients who undergo ML for large stone removal.
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